2025 is shaping up to be a turning point for bispecific therapeutics in autoimmune disease.
Historically dominated by oncology, the bispecific landscape is expanding, and autoimmune diseases are now emerging as a key area of focus. In fact, autoimmune indications account for 41% of all non-oncology bispecific assets, making them the most active therapeutic area outside of cancer.
This new report, built from Beacon Autoimmune and Beacon Bispecific data, provides a detailed snapshot of this growing pipeline.
You’ll gain strategic insight into:
- Top mechanisms of action and rising scaffold formats
- The growing role of T cell engagers in immune modulation
- Emerging targets and deal-making activity shaping 2025
You May Also Be Interested In…
Learn More About Bispecific
- The Most Comprehensive Way to Search the Bispecific Drug Development Landscape: Unique search ontologies based on Bispecific drug and trial characteristics
- Market Leading Approach to Bispecific Preclinical & Clinical Data Curation: Manual curation of key Bispecific research and development data points Bispecific research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Bispecific company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
